The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...

Patients with chronic spontaneous urticaria improved early, with benefits lasting through the 52-week follow-up for those who ...

The benefit-risk profile of finerenone (Kerendia) for heart failure and mildly reduced or preserved ejection fraction (HFmrEF ...

The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...

Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in ...

The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...

The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease ...

Regeneron's R&D expenses are projected to reach $5 billion, but the business remains highly profitable. Read why I rate REGN ...

Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

Regeneron Pharmaceuticals has purchased Quad’s shuttered printing plant in Saratoga Springs, sparking hopes for economic ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and ...